...
首页> 外文期刊>Molecular pharmacology. >Crystal structure of a cytochrome P450 2B6 genetic variant in complex with the inhibitor 4-(4-chlorophenyl)imidazole at 2.0-A resolution.
【24h】

Crystal structure of a cytochrome P450 2B6 genetic variant in complex with the inhibitor 4-(4-chlorophenyl)imidazole at 2.0-A resolution.

机译:细胞色素P450 2B6遗传变异体与抑制剂4-(4-氯苯基)咪唑的复合晶体结构,分辨率为2.0-A。

获取原文
获取原文并翻译 | 示例

摘要

The structure of the K262R genetic variant of human cytochrome P450 2B6 in complex with the inhibitor 4-(4-chlorophenyl)imidazole (4-CPI) has been determined using X-ray crystallography to 2.0-A resolution. Production of diffraction quality crystals was enabled through a combination of protein engineering, chaperone coexpression, modifications to the purification protocol, and the use of unique facial amphiphiles during crystallization. The 2B6-4-CPI complex is virtually identical to the rabbit 2B4 structure bound to the same inhibitor with respect to the arrangement of secondary structural elements and the placement of active site residues. The structure supports prior P450 2B6 homology models based on other mammalian cytochromes P450 and is consistent with the limited site-directed mutagenesis studies on 2B6 and extensive studies on P450 2B4 and 2B1. Although the K262R genetic variant shows unaltered binding of 4-CPI, altered binding affinity, kinetics, and/or product profiles have been previously shown with several other ligands. On the basis of new P450 2B6 crystal structure and previous 2B4 structures, substitutions at residue 262 affect a hydrogen-bonding network connecting the G and H helices, where subtle differences could be transduced to the active site. Docking experiments indicate that the closed protein conformation allows smaller ligands such as ticlopidine to bind to the 2B6 active site in the expected orientation. However, it is unknown whether 2B6 undergoes structural reorganization to accommodate bulkier molecules, as previously inferred from multiple P450 2B4 crystal structures.
机译:已使用X射线晶体学确定了2.0-A分辨率的人类细胞色素P450 2B6与抑制剂4-(4-氯苯基)咪唑(4-CPI)结合的K262R遗传变异体的结构。通过结合蛋白质工程,分子伴侣共表达,对纯化方案进行修改以及在结晶过程中使用独特的面部两亲物,可以生产出具有衍射质量的晶体。就二级结构元素的排列和活性位点残基的位置而言,2B6-4-CPI复合物实际上与与相同抑制剂结合的兔2B4结构相同。该结构支持基于其他哺乳动物细胞色素P450的先前P450 2B6同源性模型,并且与2B6的有限定点诱变研究以及P450 2B4和2B1的广泛研究一致。尽管K262R遗传变异体显示4-CPI的结合未发生改变,但先前已经显示了几种其他配体的结合亲和力,动力学和/或产物谱发生了变化。根据新的P450 2B6晶体结构和先前的2B4结构,残基262处的取代会影响连接G和H螺旋的氢键网络,其中细微的差异可被传导至活性位点。对接实验表明,封闭的蛋白质构象允许较小的配体(例如噻氯匹定)以预期的方向与2B6活性位点结合。但是,如先前从多个P450 2B4晶体结构推断出的那样,未知2B6是否经过结构重组以容纳更大的分子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号